Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
Clinical trial NCT05668949 · WITHDRAWN
Trial details
- NCT number
- NCT05668949
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-23
- Primary completion
- 2025-09-23
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.